Before You Fly: The Complete Checklist for Patients Seeking CAR-T in China

Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) can develop within hours. Confirm that the facility has a fully dedicated, on-site ICU with physicians certified in grading and managing severe CAR-T toxicities per the ASTCT 2019 consensus guidelines [1] (Lee et al., Biol Blood Marrow Transplant; DOI: 10.1016/j.bbmt.2018.12.758).

Grade 2+ CRS requires immediate intervention with Tocilizumab (Actemra, IL-6 receptor antagonist) and high-dose corticosteroids (Dexamethasone/Methylprednisolone) per standard ASTCT management algorithms [1]. Confirm that the hospital pharmacy has guaranteed, immediately accessible vials on-site, rather than relying on delayed emergency external procurement.

CAR-T induces prolonged cytopenias and severe B-cell aplasia / hypogammaglobulinemia. Verify that the medical team has clear protocols for routine monitoring of absolute neutrophil counts (ANC) and platelets; antimicrobial prophylaxis (PJP prevention with Trimethoprim-Sulfamethoxazole, antiviral coverage with Acyclovir/Valacyclovir, and antifungal coverage); and regular Intravenous Immunoglobulin (IVIG) replenishment.

Ensure the written agreement guarantees that if T-cell collection or biomanufacturing fails, you may either opt for a second collection attempt or decline and receive a 100% full refund of the drug payment.

Confirm that if your attending physician issues formal medical certification that clinical deterioration prevents proceeding with leukapheresis, the manufacturer provides a 100% full refund of the cell drug payment.

Ensure transparent contractual terms: if cells are harvested but treatment is halted before manufacturing commences, retention is limited to ¥100,000 RMB; if custom production has commenced, retention is capped at ¥300,000 RMB to cover consumable costs, with the balance fully refunded.

Verify that if the laboratory receives qualified T-cells but the final CAR-T product fails release criteria or quality release testing, you are entitled to discontinue therapy with a 100% full refund of the drug fee.

Long-haul flights carry significant risks of hypoxia, intracranial pressure changes, and deep vein thrombosis (DVT) in post-CAR-T patients. Most centers require a minimum observation period of 28 to 30 days post-infusion, sustained stable blood counts (Platelets ≥ 50,000/μL, Hemoglobin ≥ 8.0 g/dL, ANC ≥ 1,000/μL), absence of active fever or neurotoxicity for at least 14 days, and assistance with airline MEDIF documentation.

Demand a comprehensive English Inpatient Discharge Summary signed by the attending hematologist, detailing infusion kinetics, peak CRS/ICANS nursing logs, bone marrow aspirate/biopsy reports, multi-parameter flow cytometry / MRD assessments, and uncompressed digital DICOM discs for all PET-CT, CT, and MRI scans.

Who is responsible for your Day 30, Day 90, Day 180, and Day 360 (1-Year) evaluations? Ensure your Chinese attending physician provides an official direct communication channel (department email or direct physician-to-physician memo) to brief your local oncologist on monitoring delayed cytopenias, secondary hypogammaglobulinemia, and IVIG maintenance.

Verify that quotes separate the commercial drug from hospital care. Commercial cell products are officially priced in RMB: 赛恺泽® (Zevor-cel) carries a list price of ¥1,150,000 with a current ¥300,000 international patient reduction bringing net drug cost to ¥850,000; 福可苏® (Eque-cel) list price is ¥1,166,000. Inpatient hospital stacks vary significantly between public general wards (¥80,000–¥220,000), public international medical centers (¥150,000–¥350,000), and private international hospitals (¥250,000–¥600,000). Compare those figures against the CMDN live cost breakdown. Peri-infusion HEPA isolation typically spans 7–14 days, followed by outpatient observation. Confirm on-site ICU readiness and pharmacy stock to avoid emergency external procurement.

Several foreign governmental health programs and private insurers offer cross-border medical subsidies. Verify that the Chinese hospital has administrative workflows to provide a formal Prior Authorization Medical Dossier with standard ICD-10 C90.0 coding, a Medical Necessity Statement, and official institutional stamping on overseas reimbursement claim forms.

Payments must be wired via SWIFT directly to the hospital official institutional bank account. Never transfer funds to personal accounts or unverified facilitators. Ensure the hospital issues an Official Chinese Tax Invoice (发票 Fapiao) alongside an itemized English medical bill, which is mandatory for insurance reimbursement and tax filing.

International patients enter on an S2 Medical Visa. Because the full pathway spans 8–10 weeks (and longer if marrow recovery requires observation), ensure the hospital International Medical Department has official accreditation to issue medical invitation letters and provide in-person documentation to the local Public Security Bureau (Exit-Entry Administration) if an extension is required.

During post-infusion neutropenia, food must be freshly cooked and microbiologically safe (Neutropenic Diet). Confirm whether the hospital provides compliant meals or whether hospital-adjacent serviced apartments offer sterile cooking facilities. Verify dedicated English medical coordination during daily rounds and emergencies.